vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Envela Corp (ELA). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $80.5M, roughly 1.7× Envela Corp). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 7.4%, a 28.0% gap on every dollar of revenue. On growth, Envela Corp posted the faster year-over-year revenue change (66.6% vs 18.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-3.7M). Over the past eight quarters, Envela Corp's revenue compounded faster (42.1% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Envela Corporation is a U.S.-based company that provides recommerce services aimed at extending product lifecycles and reducing resource consumption. The company operates through two primary segments: consumer and commercial.
ADMA vs ELA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $80.5M |
| Net Profit | $49.4M | $6.0M |
| Gross Margin | 63.8% | 20.5% |
| Operating Margin | 45.1% | 9.4% |
| Net Margin | 35.5% | 7.4% |
| Revenue YoY | 18.4% | 66.6% |
| Net Profit YoY | -55.9% | 274.6% |
| EPS (diluted) | $0.20 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $80.5M | ||
| Q3 25 | $134.2M | $57.4M | ||
| Q2 25 | $122.0M | $54.9M | ||
| Q1 25 | $114.8M | $48.3M | ||
| Q4 24 | $117.5M | $48.3M | ||
| Q3 24 | $119.8M | $46.9M | ||
| Q2 24 | $107.2M | $45.3M | ||
| Q1 24 | $81.9M | $39.9M |
| Q4 25 | $49.4M | $6.0M | ||
| Q3 25 | $36.4M | $3.4M | ||
| Q2 25 | $34.2M | $2.8M | ||
| Q1 25 | $26.9M | $2.5M | ||
| Q4 24 | $111.9M | $1.6M | ||
| Q3 24 | $35.9M | $1.7M | ||
| Q2 24 | $32.1M | $1.6M | ||
| Q1 24 | $17.8M | $1.9M |
| Q4 25 | 63.8% | 20.5% | ||
| Q3 25 | 56.3% | 22.8% | ||
| Q2 25 | 55.1% | 22.6% | ||
| Q1 25 | 53.2% | 24.8% | ||
| Q4 24 | 53.9% | 23.1% | ||
| Q3 24 | 49.8% | 24.4% | ||
| Q2 24 | 53.6% | 25.1% | ||
| Q1 24 | 47.8% | 25.9% |
| Q4 25 | 45.1% | 9.4% | ||
| Q3 25 | 38.0% | 7.3% | ||
| Q2 25 | 35.1% | 5.9% | ||
| Q1 25 | 30.4% | 6.5% | ||
| Q4 24 | 32.6% | 3.9% | ||
| Q3 24 | 33.1% | 4.3% | ||
| Q2 24 | 36.6% | 4.2% | ||
| Q1 24 | 26.7% | 5.9% |
| Q4 25 | 35.5% | 7.4% | ||
| Q3 25 | 27.1% | 5.8% | ||
| Q2 25 | 28.1% | 5.0% | ||
| Q1 25 | 23.4% | 5.2% | ||
| Q4 24 | 95.2% | 3.3% | ||
| Q3 24 | 30.0% | 3.6% | ||
| Q2 24 | 29.9% | 3.5% | ||
| Q1 24 | 21.7% | 4.8% |
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $0.15 | $0.13 | ||
| Q2 25 | $0.14 | $0.11 | ||
| Q1 25 | $0.11 | $0.10 | ||
| Q4 24 | $0.45 | $0.07 | ||
| Q3 24 | $0.15 | $0.06 | ||
| Q2 24 | $0.13 | $0.06 | ||
| Q1 24 | $0.08 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $9.9M |
| Stockholders' EquityBook value | $477.3M | $67.1M |
| Total Assets | $624.2M | $96.0M |
| Debt / EquityLower = less leverage | 0.15× | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | $19.8M |
| Q4 25 | $72.1M | $9.9M | ||
| Q3 25 | $72.4M | $12.5M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.2M | ||
| Q4 24 | $72.3M | $13.5M | ||
| Q3 24 | — | $13.8M | ||
| Q2 24 | — | $14.3M | ||
| Q1 24 | — | $14.6M |
| Q4 25 | $477.3M | $67.1M | ||
| Q3 25 | $431.2M | $61.1M | ||
| Q2 25 | $398.3M | $57.8M | ||
| Q1 25 | $373.4M | $55.1M | ||
| Q4 24 | $349.0M | $52.7M | ||
| Q3 24 | $231.9M | $51.1M | ||
| Q2 24 | $188.3M | $50.2M | ||
| Q1 24 | $153.7M | $49.3M |
| Q4 25 | $624.2M | $96.0M | ||
| Q3 25 | $568.7M | $90.9M | ||
| Q2 25 | $558.4M | $82.7M | ||
| Q1 25 | $510.6M | $79.7M | ||
| Q4 24 | $488.7M | $77.9M | ||
| Q3 24 | $390.6M | $77.4M | ||
| Q2 24 | $376.4M | $73.8M | ||
| Q1 24 | $350.9M | $74.7M |
| Q4 25 | 0.15× | 0.15× | ||
| Q3 25 | 0.17× | 0.20× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | 0.21× | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.30× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-3.5M |
| Free Cash FlowOCF − Capex | $34.6M | $-3.7M |
| FCF MarginFCF / Revenue | 24.8% | -4.6% |
| Capex IntensityCapex / Revenue | 0.8% | 0.2% |
| Cash ConversionOCF / Net Profit | 0.72× | -0.59× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $1.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-3.5M | ||
| Q3 25 | $13.3M | $2.4M | ||
| Q2 25 | $21.1M | $2.6M | ||
| Q1 25 | $-19.7M | $1.1M | ||
| Q4 24 | $50.2M | $3.7M | ||
| Q3 24 | $25.0M | $3.4M | ||
| Q2 24 | $45.6M | $-789.5K | ||
| Q1 24 | $-2.2M | $3.8M |
| Q4 25 | $34.6M | $-3.7M | ||
| Q3 25 | $-1.1M | $2.2M | ||
| Q2 25 | $18.7M | $2.1M | ||
| Q1 25 | $-24.4M | $746.6K | ||
| Q4 24 | $47.5M | $3.2M | ||
| Q3 24 | $24.0M | $1.5M | ||
| Q2 24 | $43.6M | $-1.3M | ||
| Q1 24 | $-4.6M | $3.3M |
| Q4 25 | 24.8% | -4.6% | ||
| Q3 25 | -0.8% | 3.8% | ||
| Q2 25 | 15.3% | 3.9% | ||
| Q1 25 | -21.2% | 1.5% | ||
| Q4 24 | 40.4% | 6.7% | ||
| Q3 24 | 20.0% | 3.1% | ||
| Q2 24 | 40.7% | -2.9% | ||
| Q1 24 | -5.6% | 8.4% |
| Q4 25 | 0.8% | 0.2% | ||
| Q3 25 | 10.7% | 0.4% | ||
| Q2 25 | 2.0% | 0.8% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 1.0% | ||
| Q3 24 | 0.9% | 4.2% | ||
| Q2 24 | 1.9% | 1.1% | ||
| Q1 24 | 2.9% | 1.1% |
| Q4 25 | 0.72× | -0.59× | ||
| Q3 25 | 0.36× | 0.72× | ||
| Q2 25 | 0.62× | 0.94× | ||
| Q1 25 | -0.73× | 0.45× | ||
| Q4 24 | 0.45× | 2.34× | ||
| Q3 24 | 0.70× | 2.05× | ||
| Q2 24 | 1.42× | -0.50× | ||
| Q1 24 | -0.12× | 1.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
